NCT01352897已完成不适用
A Registry to Collect Data of Efficacy and Safety Between Rosuvastatin, and Atorvastatin and Simvastatin In Subjects With Type IIa and IIb Hypercholesterolaemia Under Real Clinical Settings
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 800
- 试验地点
- 1
- 主要终点
- Percentage of patients who maintain US NCEP ATP III LDL-C target goals after long-term therapy
研究概览
简要总结
The objective of this follow-up retrospective study is to evaluate the long term efficacy and safety of rosuvastatin in reducing lipid parameters in clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primary hypercholesterolemia
- •Subjects from first rosuvastatin Registry study
排除标准
- 未提供
结局指标
主要结局
Percentage of patients who maintain US NCEP ATP III LDL-C target goals after long-term therapy
时间窗: Up to 8 years
次要结局
- LDL-cholesterol levels(Up to 8 years)
- HDL-cholesterol levels(Up to 8 years)
- Proportion of patients having raised levels of serum CK or ALT(Up to 8 years)
研究者
研究点 (1)
Loading locations...
相似试验
Enrolling By Invitation
不适用
Observational Registry for Iltamiocel Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress IncontinenceStress Urinary IncontinenceNCT06743620Cook MyoSite96
已完成
不适用
Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201Macular EdemaRetinal Vein OcclusionNCT02956330Clearside Biomedical, Inc.20
Enrolling By Invitation
2 期
Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyNeovascular Age-related Macular DegenerationWet Macular DegenerationNCT03999801AbbVie865
Enrolling By Invitation
2 期
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDNeovascular Age-Related Macular Degeneration (nAMD)Gene TherapyWet AMDwAMDnAMDNCT05210803AbbVie116
Enrolling By Invitation
2 期
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyDiabetic Retinopathy, DRNCT05296447AbbVie100